Skip to content

Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis

Cyclobenzaprine Treatment for Muscle Cramps in Cirrhotic Patients

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02642861
Enrollment
200
Registered
2015-12-30
Start date
2018-10-31
Completion date
2019-12-31
Last updated
2018-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Brief summary

\- Cyclobenzaprine, is a muscle relaxer medication used to relieve skeletal muscle spasms. It is one of the best-studied drug for this application.

Detailed description

Although a number of mechanisms for cramps in liver disease have been postulated and have been targeted by medical therapies, a clear picture of the causal events has not emerged. Several agents as vitamin E, human albumin, zinc, taurine, eperisone hydrochloride and branched-chain amino acids have shown some benefit in small uncontrolled studies, although large randomized controlled trials are lacking. \- Cyclobenzaprine, is a muscle relaxer medication used to relieve skeletal muscle spasms. It is one of the best-studied drug for this application.

Interventions

cyclobenzaprine administration for 2 weeks

DRUGCalcium Carbonate

Calcium carbonate for 2 weeks

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Liver cirrhosis and has frequent muscle cramps

Exclusion criteria

* Allergy to cyclobenzaprine * Encephalopathy. * Receiving antidepressant drugs

Design outcomes

Primary

MeasureTime frameDescription
Number of muscle cramps3 monthsThe number of muscle cramps

Countries

Egypt

Contacts

Primary ContactSherief M. Abd-Elsalam, Consultant
sherif_tropical@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026